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INTRODUCTION 
 
Diabetic nephropathy  (DN) is the chronic loss of kidney function occurring in 
those with diabetes mellitus. It is a serious complication, affecting approximately one-
quarter of adult diabetics in the United States. It is usually slowly progressive over 
years.  
Pathophysiologic abnormalities in DN begin with long-standing poorly 
controlled blood glucose levels. This is followed by multiple changes in the filtration 
units of the kidneys, the nephrons. (There are normally about 3/4-1 1/2 million nephrons 
in each adult kidney).Initially, there is constriction of the efferent arterioles and 
dilatation of afferent arterioles, with resulting glomerular capillary hypertension and 
hyperfiltration; this gradually changes to hypofiltration over time. Concurrently, there 
are changes within the glomerulus itself: these include a thickening of the basement 
membrane, a widening of the slit membranes of the podocytes, an increase in the 
number of mesangial cells, and an increase in mesangial matrix. This matrix invades the 
glomerular capillaries and produces deposits called Kimmelstiel-Wilson nodules.  
The mesangial cells and matrix can progressively expand and consume the entire 
glomerulus, shutting off filtration. As this process affects more and more glomeruli, 
filtration in both kidneys progressively declines: the pathological process 
called nephrosclerosis. 
  
Type 2 diabetes mellitus (DM) is the most common single cause of end-stage 
renal disease. Albuminuria is the most commonly used marker to predict onset of 
diabetic nephropathy (DN) without enough sensitivity and specificity to detect early 
DN. 
Cyclophilin A (CypA) is an 18-kDa protein with ubiquitous characteristics. It is 
mostly distributed in the cytoplasm and facilitates protein folding and protein 
trafficking. 
Interestingly, sCypA was also detected in plasma of diabetic patients and was 
shown to be secreted by monocytes in response to hyperglycemia, indicating that 
sCypA could be a potential secretory marker in type 2 DM. As a product directly 
produced by kidney, urine could be best measure for  detection of renal injury. 
Therefore in this study the urinary level of Cyp A in the patients with Diabetic 
nephropathy were assayed. 
 
 
 
 
 
 
  
 
REVIEW OF LITERATURE 
Definition and Natural History 
It is known that DN can be detected before the onset of decreased glomerular 
filtration rate (GFR) in most patients by detecting abnormal amounts of albumin in the 
urine. Two stages have been designated: microalbuminuria (defined as urine albumin 
between 30 and 300 mg/24 h, 20-200 µg/min on a timed sample, or spot urine albumin 
to creatinine ratio 30-300 mg/g) and albuminuria, also termed clinical albuminuria, 
macroalbuminuria, and overt nephropathy (>300 mg/24 h, >200 µg/min on a timed 
sample, or spot urine albumin to creatinine [ACR] ratio >300 mg/g). Short-term 
hyperglycemia, exercise, urinary tract infections, marked hypertension, heart failure, 
and acute, febrile illness can cause transient elevations of Albumin Creatinine Ratio 
(ACR) [1]; There is also marked day-to-day variability in Urine albumin excretion, so 
that at least two to three urine specimens done should show elevated levels before a 
patient is designated as having microalbuminuria. 
In type 1 diabetes mellitus, microalbuminuria is rarely present at diagnosis, but 
persistent and untreated microalbuminuria will progress to albuminuria in 30%-80% of 
individuals over 10-15 yrs, and of those, 50%-78% will progress to 
Diabetic nephropathy over the next 10-18 yr [2]. Hypertension usually develops as a 
complication of nephropathy. In type 2 diabetes mellitus, microalbuminuria and even 
albuminuria may be present at or soon after diagnosis, in part due to the fact that 
  
diabetes has often already been present for years. If left untreated, 20%-40% of such 
patients will develop overt nephropathy, with only approx 20% of those patients 
progressing to DN over the next 20 yr [3]. Hypertension is frequently already present at 
the time of diagnosis of diabetes, often as part of the metabolic syndrome. Based on the 
current evidence that early intervention may slow the progression of diabetic kidney 
disease, it is now the standard of care to do annual screening because microalbuminuria, 
in type 1 diabetes starts at puberty or 5 yr after diagnosis, and in type 2 diabetes begins 
at diagnosis [4]. 
However, cross-sectional studies have found decreased GFR in the absence of 
increased urine albuminexcretion (UAE) in a substantial percentage of adults with type 
2 diabetes [5]. In the Third National Health andNutrition Examination Survey, which 
collected demographic and health information from a nationally representative sample 
of the US population, 13% of adults with type 2 diabetes had a GFR <60 mL/min/ 1.73 
m2. Among this population, an absence of increased UAE (defined in this study as a 
spot urine ACR ≥17 mg/g in men and ≥25 mg/g in women) was noted in approx. 40%, 
whereas absence of both increased UAE and diabetic retinopathy was noted in 30% [5]. 
Decreased GFR in the absence of increased UAE among adults with both type 1 and 2 
diabetes have also been reported in other studies [6]. In follow-up, the rates of decline 
of GFR in those with type 2 diabetes with initial GFR levels <60 mL/min/1.73 m2 were 
similar, regardless of the presence or absence of albuminuria [7]. Thus, these studies 
demonstrate that substantial declines in GFR may be noted in adults with type 1 and 2 
diabetes in the absence of increased UAE. Because these studies did not perform kidney 
biopsies, investigators could only speculate on the etiology of decreased GFR in the 
  
absence of increased UAE. Pathological evidence of DN has been documented in adults 
with diabetes even in the absence of increased UAE [8,9]. In addition, older patients 
with type 2 diabetes may also have vascular and tubulo-interstitial changes owing to the 
presence of comorbid conditions, including long-standing hypertension and renal 
vascular disease, and potential senescence of glomeruli owing to aging itself [10,11]. 
Conversely, studies have also reported a range of biopsy findings from normal to typical 
diabetic changes and frequently other kidney diseases in adults with type 2 diabetes and 
increased UAE [12]. Therefore, in addition to yearly screening for albuminuria, the 
yearly measurement of serum creatinine with estimation of GFR using the adjusted 
modification diet in renal disease (MDRD) [13] or other formulae [14] should also be 
carried out. 
Diabetes is the most common cause of end-stage renal disease (ESRD) in the 
United States today.(15) Approximately 40% of patients with type 1 diabetes and 5 - 
15% of patients with type 2 diabetes eventually develop ESRD, although the incidence 
is substantially higher in certain ethnic groups.(16) 
This is thought to be a potentially preventable calamity. Sensitive tests are 
available to identify patients with renal involvement early in the clinical course, when 
preventive measures may have greatest impact. 
The pathophysiologic mechanisms of diabetic nephropathy are incompletely 
understood but include glycosylation of circulating and intrarenal proteins, 
hypertension, and abnormal intrarenal hemodynamics. The earliest demonstrable 
abnormalities include intrarenal hypertension, hyperfiltration (increased glomerular 
  
filtration rate [GFR]), and microalbuminuria. Clinically, the most important screening 
tool for identifying early nephropathy is detection of microalbuminuria. 
Risk factors for development of diabetic nephropathy include hyperglycemia, 
hypertension, positive family history of nephropathy and hypertension, and smoking. 
Key elements in the primary care of diabetes include glycemic control, blood pressure 
control, and screening for microalbuminuria. In general, the goal for glycemic control is 
a blood glucose level as close to normal and HbA1c <7% as possible without causing 
hypoglycemia. Blood pressure control is important as glucose control, especially after 
the onset of renal damage, and blood pressure should be consistently <130/85. 
Screening for diabetic nephropathy involves monitoring at least yearly for urinary 
albumin excretion >30 mg per day. 
Diabetic Kidney Disease was previously known as diabetic nephropathy and is 
defined as diabetes with albuminuria (ratio of urine albumin to creatinine ≥ 30 mg/g), 
impaired glomerular filtration rate (<60 mL/min/1.73 m2), or both and is the single 
strongest predictor of mortality in patients with diabetes [17]. Today, DKD 
encompasses not only diabetic nephropathy but also atheroembolic disease, ischemic 
nephropathy, and interstitial fibrosis that occurs as a direct result of diabetes. 
 
Diabetic nephropathy (DN) is one of the major causes of end-stage renal failure 
worldwide [18]. Clinically, microalbuminuria is an important index to assess the 
progression of DN [19]. However, it is not accurate to evaluate the severity or prognosis 
simply based on the degree of proteinuria. It is now well recognized that not all diabetic 
  
patients who develop renal function failure have massive albuminuria [20]. Therefore, 
nephrologists and endocrinologists should be aware of the significance of pathological 
changes of DN in their clinical practice. Specifically, nondiabetic renal disease 
(NDRD), which might commonly be superimposed with diabetic renal lesions in some 
patients with type 2 diabetes, could only be confirmed and excluded by biopsy [21]. 
Etiology and Epidemiology 
WHO estimates that 347 million people worldwide suffer from diabetes. In the 
region of Africa, around 20 million are living with diabetes. This figure is expected to 
double by 2030. In comparison to other world regions, Africa has the highest percentage 
of undiagnosed diabetes cases reaching 62% and the lowest diabetes related health 
expenditure.  
Globally, an estimated 422 million adults are living with diabetes mellitus, 
according to the latest 2016 data from the World Health Organization (WHO).Diabetes 
prevalence is increasing rapidly; previous 2013 estimates from the International 
Diabetes Federation put the number at 381 million people having diabetes. The number 
is projected to almost double by 2030.Type 2 diabetes makes up about 85-90% of all 
cases. Increases in the overall diabetes prevalence rates largely reflect an increase in 
risk factors for type 2, notably greater longevity and being overweight or obese. 
Diabetes mellitus occurs throughout the world, but is more common (especially 
type 2) in the more developed countries. The greatest increase in prevalence is, 
however, occurring in low- and middle-income countries including in Asia and Africa, 
where most patients will probably be found by 2030.The increase in incidence in 
developing countries follows the trend of urbanization and lifestyle changes, including 
  
increasingly sedentary lifestyles, less physically demanding work and the global 
nutrition transition, marked by increased intake of foods that are high energy-dense but 
nutrient-poor (often high in sugar and saturated fats, sometimes referred to as 
the Western pattern diet). The risk of getting type 2 diabetes has been widely found to 
be associated with lower socio-economic position across countries. 
Diabetes is fast gaining the status of a potential epidemic in India with more than 
62 million diabetic individuals currently diagnosed with the disease. In 2000, India 
(31.7 million) topped the world with the highest number of people with diabetes 
mellitus followed by China (20.8 million) with the United States (17.7 million) in 
second and third place respectively. According to Wild et al. the prevalence of diabetes 
is predicted to double globally from 171 million in 2000 to 366 million in 2030 with a 
maximum increase in India. It is predicted that by 2030 diabetes mellitus may afflict up 
to 79.4 million individuals in India, while China (42.3 million) and the United States 
(30.3 million) will also see significant increases in those affected by the disease. India 
currently faces an uncertain future in relation to the potential burden that diabetes may 
impose upon the country. Many influences affect the prevalence of disease throughout a 
country, and identification of those factors is necessary to facilitate change when facing 
health challenges. 
Diabetic nephropathy is one of the leading causes of chronic renal failure in 
India. It has been reported that among 4837 patients with chronic renal failure seen over 
a period of 10 years, the prevalence of diabetic nephropathy was 30.3% followed by 
chronic interstitial nephritis (23.0%) and chronic glomerulonephritis (17.7%) 
Pathological Changes of DN 
  
The most significant and consistent pathological changes identified in renal 
biopsies of clinical DN patients are the glomerular lesions [22] which are, especially, 
diffuse and nodular mesangial expansion and Glomerular Basement Membrane (GBM) 
thickening [23]. Diffuse mesangial expansion, which develops at as early as 5th year 
since the onset of diabetes, is the earliest observable change by light microscopy [24]. 
The mesangial fractional volume [Vv(Mes/glom)] is correlated with albumin excretion 
rate (AER) and Glomerular Filtration Rate (GFR) in both type 1 [25] and type 2 
diabetes [26]. As the disease advances, diffuse mesangial expansion progressively 
develops into nodular accumulations of mesangial matrix in the late stage of the DN. 
These nodular lesions, also known as Kimmelstiel-Wilson nodules, can be observed in 
about 25% of patients with advanced DN [27]. Nodular lesions and diffuse lesions are 
two stages of DN. Compared to the patients with diffuse mesangial expansion, those 
patients with nodular diabetic glomerulosclerosis present with more severe renal 
damage, longer diabetic durations, and poorer renal prognosis [28]. 
GBM thickening can be observed within 2–8 years after the onset of diabetes. It is an 
early lesion which could be detected and measured by electron microscopy (EM) [29]. 
GBM width tends to increase linearly according to diabetes duration in type 1 diabetes 
[30]. Vv(Mes/glom) and GBM width together explain 59% of the AER variability in a 
group of 125 patients of type 1 diabetes [25]. 
Although diabetic glomerular lesions have been the focus of the investigation on 
DN, the extraglomerular lesions are also involved in the progression of the disease. 
Tubulointerstitial lesions, including tubular atrophy, interstitial inflammation, and 
tubulointerstitial fibrosis, are closely related to renal function loss in the progression 
  
towards ESRD in patients with preexisting renal insufficiency [31]. Since DN is a kind 
of diabetic microangiopathy, hyalinosis occurs in both afferent and efferent arterioles. 
The hyalinosis of the efferent arteriole is a typical lesion by which diabetic nephropathy 
could be differentiated from hypertensive nephropathy [32]. 
There is increasing recognition of lesions like glomerular endothelial injury [22], 
podocyte impairment [33], and glomerulotubular junctions abnormalities in DN [34].  
 
 
 
 
Histopathology of DKD 
Mesangial expansion caused by increased matrix secretion and cell enlargement 
is the first change seen on light microscopy, whereas electron microscopy demonstrates 
a thickened basement membrane and podocyte effacement [24]. In the vessels, intimal 
hyaline thickening is present initially and later progresses to arterial hyalinosis of the 
afferent and efferent arterioles which later leads to glomerular hyperfiltration [35, 36]. 
Diffuse diabetic glomerulosclerosis and Kimmelstiel-Wilson nodules (nodular 
glomerulosclerosis) are seen only later in the disease, although the latter is not always 
seen on biopsy as is classically taught [37]. Ultrastructurally, podocytes suffer 
hypertrophy and then foot process effacement which leads to functional changes such as 
  
increased albumin excretion [24, 35]. It should be noted that, in patients with type 2 
diabetes, GFR loss can occur independently of albuminuria [36, 38, 39] and it has been 
demonstrated that microalbuminuria is observed in only 45% of this population [40]. 
The histopathologic change of DKD has been attributed to diabetic macroangiopathy as 
opposed solely to microangiopathy and has also been attributed to aging, 
atherosclerosis, hypertension, and episodes of acute kidney injury [36, 39, 41]. 
 
 
 
Pathways of DKD 
Previously, the above histopathologic changes were attributed primarily to 
metabolic and hemodynamic derangements seen in diabetes, the latter referring to the 
hyperfiltration which occurs as a result of efferent arteriolar vasoconstriction due to an 
activated renin-angiotensin-aldosterone system (RAAS). However, it has become 
increasingly evident over the years that hyperglycemia in and of itself is not the sole 
cause of DKD, although inarguably, it plays a major role. Several pathophysiologic 
pathways are involved in the development of DKD, and this review will attempt to 
elucidate those pathways and hopefully shed some light on therapeutic options that may 
one day play a role in quelling the epidemic of DKD and suppressing progression to 
ESRD. 
  
Hemodynamic Pathways of DKD 
Activation of the RAS leads to increased angiotensin II levels which 
subsequently cause efferent arteriolar vasoconstriction. Elevated levels of angiotensin II 
are associated with increased albuminuria and nephropathy in both humans and mice 
[35, 42, 43]. ACEIs and ARBs have a long track record in reducing the doubling rate of 
creatinine, albuminuria, and progression to nephropathy, ESRD, and death 
[28, 30, 31, 44]. Another potent vasoconstrictor of the efferent arteriole is endothelin-1 
(ET-1). ET-1 has various physiologic functions in the kidney that mimic RAS including 
mediating vasoconstriction and hence playing a role in hypertension, endothelial 
dysfunction, inflammation, and fibrosis [45]. Additionally, increased ET-1 expression 
activates a signaling cascade which leads to mesangial cell hypertrophy and 
proliferation as well as extracellular matrix (ECM) production. It is also thought to 
activate receptors that directly increase glomerular permeability, hence leading to 
worsening albuminuria and progression of DKD [45]. 
This pathway was first detailed by Brownlee in Nature in 2001 [46]. He helped 
clarify that hyperglycemia leads to increased glycolysis which then upregulates four 
distinct entities: the polyol pathway, hexosamine pathway, production of advanced 
glycation end products (AGEs), and activation of protein kinase C (PKC). Before going 
into the details of each of the above pathways, a review of glycolysis is worthwhile. 
Glycolysis is the biochemical pathway in which glucose is broken down by cells to 
make energy. Intracellular glucose is first phosphorylated into glucose-6-phosphate and 
then fructose-6-phosphate. One step later glyceraldehyde-3-phosphate becomes 1,3-
diphosphoglycerate with the help of glyceraldehyde-3-phosphate dehydrogenase. This is 
  
important because glyceraldehyde-3-phosphate dehydrogenase is inhibited by excess 
superoxide produced by the electron-transport chain which occurs in the setting of 
hyperglycemia [46–48]. Inhibition of  glyceraldehyde-3-phosphate dehydrogenase 
prevents glycolysis from taking place and causes an upregulation of upstream 
components of glycolysis, specifically glucose, glucose-6-phosphate, and fructose-6-
phosphate, hyperglycemia). 
The Polyol Pathway 
The polyol pathway is upregulated as a result of excess of hyperglycemia. 
Glucose is first converted to sorbitol via the NADPH-dependent enzyme, aldose 
reductase; sorbitol is then converted to fructose using NAD+ as a cofactor [46]. The 
reduction of glucose to sorbitol results in decreased intracellular NADPH levels, a 
cofactor involved in regenerating the antioxidant, reduced glutathione (GSH). 
Decreased levels of GSH are thought to contribute to increased intracellular oxidative 
stress which in turn causes increased cell stress and apoptosis [49]. Additionally, the 
oxidation of sorbitol to fructose results in an increased intracellular NADH :  NAD+ 
ratio which also inhibits GADPH activity, thus propagating the inhibition of glycolysis. 
The increased NADH : NAD+ ratio also increases formation of methylglyoxal and 
diacylglycerol, precursors of the AGE and PKC pathways [46]. Finally, the end product 
of the polyol pathway, fructose, has also recently emerged as a potential nephrotoxin. In 
a diabetic murine model, endogenous production of fructose through the polyol pathway 
led to increased proteinuria, reduced GFR, and increased glomerular and proximal 
tubular injury when compared to mice with lower levels of endogenous fructose.  
  
The Hexosamine Pathway 
The hexosamine pathway stems from the third step of glycolysis, fructose-6-
phosphate, which is converted to glucosamine-6-phosphate by the enzyme glutamine: 
fructose-6-phosphate amidotransferase (GFAT).Glucosamine-6-phosphate is then used 
as a substrate to increase transcription of inflammatory cytokines tumor necrosis factor-
α (TNF-α) and transforming growth factor-β1 (TGF-β1) [46].  
Advanced Glycation End Products 
Advanced glycation end products (AGEs) are the result of irreversible glycation 
of proteins that occurs in the presence of intracellular hyperglycemia [35, 46, 50]. Three 
pathways are primarily responsible for the production of AGE precursors: oxidation of 
glucose to make glyoxal, degradation of Amadori products, and aberrant glycolysis 
which shunts glyceraldehyde-3-phosphate into forming methylglyoxal [51]. Once 
formed, AGEs damage cells by modifying or impairing the function of both intracellular 
and extracellular proteins [60]. For example, AGE modifies both laminin and type IV 
collagen and was shown to increase the permeability of the glomerular basement 
membrane (GBM) [52–55]. Additionally increased concentrations of AGE are known to 
dose-dependently increase expression of fibronectin and collagen types I and IV which 
are thought to lead to increased density and expansion of the extracellular matrix in the 
kidney [52, 56–60]. AGEs themselves can bind various proinflammatory receptors 
which then activate downstream production cytokines such as IL-1, IL-6, and TNF-α, 
growth factors such a TGF-B1, vascular endothelial growth factor (VEGF), platelet-
derived growth factor subunit B (PDGF-B), connective tissue growth factor (CTGF), 
and increased generation of reactive oxygen species (ROS) [36, 52,61, 62]. VEGF is 
  
necessary for survival of endothelial cells, podocytes, and mesangial cells whereas 
CTGF is a profibrotic agent; both have been implicated in diabetic nephropathy 
[52, 63, 64]. 
 The PKC Pathway 
The PKC pathway, like the AGE pathway, stems from the fourth step in 
glycolysis. Hyperglycemia drives the conversion of glyceraldehyde-3-phosphate into 
dihydroxyacetone phosphate (DHAP) and ultimately diacylglycerol (DAG) which is a 
cofactor for PKC activation [65]. In the presence of hyperglycemia, DAG is chronically 
upregulated and contributes to sustained PKC activation [66]. PKC is thought to 
contribute to DKD in various ways. It increases activity levels of prostaglandin E2 and 
nitric oxide [67–69] leading to vasodilation of the afferent arteriole and augmentation of 
angiotensin II’s actions on the efferent arteriole [70, 71]; these actions collectively 
contribute to glomerular hyperfiltration [65]. In the later stages of diabetic nephropathy, 
there is a state of progressive deficiency in nitric oxide which has been associated with 
severe proteinuria, declining renal function, and hypertension [72, 73]. PKC also 
mediates VEGF which, as noted above, is linked to abnormal intrarenal blood flow and 
capillary permeability and is thought to play a role in the development of 
microalbuminuria [65, 74]. PKC activation also increases CTGF and TGF-β levels as 
well as production of fibronectin and type IV collagen and contributes to GBM 
thickening and ECM accumulation [65]. 
Inflammatory Pathways of DKD 
  
The inflammatory pathway supports the idea that DKD is not solely a result of 
uncontrolled hemodynamics and hyperglycemia but is also a consequence of a 
chronically activated innate immune system and a low-grade inflammatory state in 
patients with diabetes [75, 76]. Inflammatory-mediated renal injury was reviewed 
recently and is summarized here [75]. 
NF-κB is a transcription factor that regulates the expression of multiple genes 
related to inflammation, immunity, apoptosis, and chemoattractant protein-1, amongst 
others [77, 78], and localizes to glomerular, interstitial, and tubular epithelial cells in the 
human kidney. Hyperglycemic conditions are known to increase expression of NF-κB 
[79]. In DKD [77, 80], NF-κB activation correlates with proteinuria and interstitial cell 
infiltration [77, 78, 80]. Proteinuria is known to further stimulate NF-κB and contributes 
to persistent proteinuria in a cyclic fashion [78]. 
The Janus kinase/signal transducers and activators of transcription (JAK/STAT) 
signaling pathway is a way for chemical signals outside of a cell to be relayed to gene 
promoters at the DNA level. JAK2 is present in renal and vascular tissue [81]. It is 
activated by ROS caused by hyperglycemic states and is associated with hypertrophy of 
mesangial cells [75]. Berthier et al. demonstrated that JAK2 mRNA levels inversely 
correlated with estimated glomerular filtration rate (eGFR) in patients with diabetic 
nephropathy [82]. 
Inflammatory cytokines such as TNF-α and interleukins 1, 6, and 18 (IL-1, IL-6, and 
IL-18, resp.) are expressed in greater proportions in the kidneys of diabetic models 
when compared to nondiabetic controls [83, 84]. In diabetic rat models, increased 
expression of TNF-α and IL-6 was also associated with increased kidney weight and 
  
urine albumin excretion [83]. In patients with DKD, serum IL-18 and TNF-α levels 
were higher in patients with diabetes than nondiabetic controls. IL-18 and TNF-α levels 
also correlated positively with the degree of albuminuria in the patients with diabetes 
[85, 86]. At the cellular level, these cytokines are thought to increase vascular 
endothelial cell permeability, contribute to glomerular hypercellularity and GBM 
thickening, induce apoptosis of endothelial cells, and can be directly toxic to renal cells 
[87–95]. 
Alternative Pathways of DKD 
Autophagy is a highly conserved protective mechanism that allows cells and 
organisms to maintain homeostasis during periods of cell starvation or oxidative stress 
[96, 97]. It involves intracellular degradation of cytotoxic proteins and organelles by 
lysosomes whenever a cell is experiencing stress [97, 98]. Decreased autophagic 
activity has been demonstrated in both obesity and diabetes [99–101] suggesting that 
autophagy is hampered in the setting of hypernutrition [102]. Podocytes are known to 
have a high basal level of autophagy [101]. In vitro studies of podocytes exposed to 
high glucose conditions demonstrated defective autophagy which resulted in podocyte 
injury [101]. On renal biopsy of obese patients, autophagic activity was decreased in 
proximal tubular epithelial cells when compared to nonobese patients suggesting that 
obese patients with diabetes may be prone to renal injury due to suppressed autophagy 
[102]. Dietary restriction in rats was shown to improve urinary albumin excretion and 
creatinine clearance and increase levels of Sirt1, a positive regulator of autophagy 
[103]. 
  
Another conserved evolutionary mechanism is linked to the sodium-glucose transporter 
2 (SGLT2) in the proximal tubule. SGLT2 is a low-affinity and high-capacity 
transporter and is responsible for >90% of glucose reabsorption in the proximal tubule 
[51, 104, 105]. Animals with a genetic deficiency of SGLT2 lose approximately 60% of 
their filtered glucose into the urine [104]. In settings of hyperglycemia, there is 
upregulation of SGLT2 expression which is believed to be of evolutionary benefit as it 
allows for glucose reabsorption and hence energy conservation for both the body and 
brain [104, 106]. Unfortunately, in settings of hyperglycemia due to diabetes, this 
mechanism is counterproductive and further contributes to a hyperglycemic state. 
 
Natural clinical course of diabetic kidney disease 
 
The natural history of DN is divided into five stages (2): 
Stage 1: Renal pathology develops at the onset of diabetes. The growth of the kidney 
increases by several centimetres. By the time of diagnosis, the GFR and urinary albumin 
excretion (UAE) have been increased. It can be controlled at this level by onset of 
insulin. 
Stage 2: The second stage typically lasts for 5-15 years after diagnosis of diabetes. The 
characteristics of the second stage include: 
1. GFR remains elevated due to hyperfiltration. 
2. Kidneys remain hypertrophied and UAE rate stays normal. 
  
Stage 3: The characteristics of stage three are: 
1. Microalbuminuria is present. It occurs in 30-50% of patients after diabetes onset, 
80% of whom go on to develop overt nephropathy over 10-15 years. 
2. GFR remains elevated or returns to normal range 
3. Blood pressure starts to rise in 60% of patients 
Histological changes-progression is as seen in stage two. 
Stage 4: This stage is also known as clinical nephropathy or overt nephropathy. The 
characteristic histological features of stage four are formation of the Kimmelstiel-
Wilson nodule (focal glomerular sclerosis) and macroproteinuria. It can progress to 
nephrotic in 30% of patients or may decline in 80% depending on deterioration of GFR. 
Stage 5: As the GFR continues to decline, ESRD may develop. DN is considered the 
most common cause of ESRD because of associated autoimmune neuropathy and 
cardiac disease. 
The stages of chronic kidney disease (CKD) are mainly based on measured or estimated 
GFR. There are five stages but kidney function is normal in stage 1 and minimally 
reduced in stage 2 (Table 1). 
 
 
  
 
Table 1 
 
Stages of diabetic nephropathy [modified from the renal association] 
Stage GFR 
(ml/min/1.73 
m2 ) 
Description Management 
1 >90 Normal or increased 
GFR with another 
evidence of renal 
damage 
Screening CKD and risk reduction 
2 60-89 Slightly decreased GFR 
with another evidence 
of renal damage 
Diagnosis and treatment: slow 
progression of CKD; comorbidities 
and cardiovascular disease; risk 
reduction 
3a 45-59 Moderately decreased 
GFR without evidence 
Evaluate and treat complication 
  
of renal damage 
3b 34-40 Irreversible renal 
damage 
 
4 15-29 Severely decreased 
GFR without evidence 
of renal damage 
Prepare for renal replacement 
therapy 
5 <15 Established renal failure Renal replacement if uremic 
 
Diabetic nephropathy is classically defined as a progressive increase in urine 
albumin excretion, accompanied by rising blood pressure and a relentless decline in 
glomerular filtration, culminating eventually in end-stage renal failure [107]. In the 
presence of retinopathy and long duration of diabetes, diabetic glomerulosclerosis is 
generally accepted to be the cause. Although it was suggested many years ago that 
nephropathy was one of a triad of complications of diabetes, the other components of 
which are retinopathy and vascular disease [108], it is only relatively recently that the 
enormous impact of premature cardiovascular disease on people with any evidence of 
diabetic nephropathy has been fully recognized. Thus, many diabetic people, even with 
early nephropathy, and particularly with type 2 diabetes, do not progress to end-stage 
  
renal disease (ESRD), but die prematurely of cardiovascular disease. A modern 
definition of diabetic nephropathy might thus encompass a state of greatly increased 
cardiovascular risk, accompanied. If untreated, by a progressive decline in renal 
function and associated with diabetic retinopathy.  
The progressive, continuous increase in urinary albumin excretion is generally 
considered in categorical stages to help clinical and research interpretation. The 
divisions have been made partly on the basis of renal risk but are to some extent 
arbitrary. Classification for research purposes is generally done by estimation of urine 
albumin excretion rates in timed urine collections, but for clinical purposes, calculation 
of the albumin: creatinine ratio in an early morning urine sample is sufficient. 
Microalbuminuria is defined as an increase in urine albumin excretion above normal, 
but which is not detectable by conventional dip-stick testing, whilst proteinuria 
represents an increase in urine albumin that is detectable by conventional dip-stick 
testing.  
In type 1 diabetes, abnormalities of renal function, including glomerular hyper 
filtration (elevated glomerular filtration rate, GFR) [109], increased albumin excretion 
rate (AER) [110, 111] and increased renal size [109, 110] are apparent at diagnosis. 
With initiation of insulin treatment, GFR returns to normal in the majority [109, 110] 
and AER probably in all patients [112-114]. However, in 25-40% of patients, GFR 
remains above normal [109, 115]. Although it has been suggested that these hyper-
filtering patients will progress to nephropathy, most [116, 117], but not all [118], 
longitudinal studies indicate that they are not at higher risk than patients who do not 
have persistent hyperfiltration.  
  
In those patients who will never develop nephropathy, albumin excretion remains 
normal, except during periods of particularly poor glucose control, or during acute 
intercurrent illness, when a transient increase in AER into the microalbuminuric or even 
proteinuric range may occur.  
In those patients who eventually reach end-stage renal failure, a progressive rise 
in AER occurs, with microalbuminuria developing within the first 10 years of diabetes. 
Some studies have suggested that AER remains normal for several years after diagnosis 
[113, 114, 119], although others suggest that the prevalence of microalbuminuria is 6-
19% within 1-5 years' duration of diabetes [120, 121]. The explanation for such marked 
differences is unclear, and they seem unlikely to be due simply to differences in 
glycaemic control. The prevalence of microalbuminuria thereafter is related to duration 
of diabetes, and reaches 40-50% after 30 years [122, 123], although the proportion is 
falling in more recent reports of cohorts [120, 124]. Approximately 1.5-2.5% per annum 
of patients with normal AER develop microalbuminuria [125-127], although the 
incidence can be reduced with extremely good glycaemic control [128]. The factors 
reported most strongly and consistently to influence the transition from normal albumin 
excretion to microalbuminuria are baseline AER, blood glucose control, blood pressure 
and the presence of retinopathy. Smoking and the presence of dyslipidaemias are less 
consistently associated. Not surprisingly, those patients with an AER in the 'high 
normal' range are more likely to develop microalbuminuria than those in the lower 
range: > 7.4 mg/L [129], > 10ug/min [126], and > 11 mg/24 h [125]. Those who do 
develop microalbuminuria have a faster rate of increase in AER in the 2-5 years before 
microalbumin-uria is evident than those whose albumin excretion remains normal [130]. 
  
There may be a period of 'intermittent' microalbuminuria before microalbuminuria 
becomes persistent [131], presumably because of the high day-to-day variation in AER 
[132].  
Early studies suggested that approximately 80% of microalbuminuric type 1 
diabetic patients would develop proteinuria [133-135]. However, more recent studies 
suggest that in approximately 30% of micro-albuminuric patients, AER reverts to 
normal, 50% remain microalbuminuric and 20% progress to pro-teinuria over a 5-9-year 
period [114, 136, 137]. The risk of developing proteinuria, however, remains much 
greater in those with microalbuminuria than in those with a normal AER. The reasons 
for the discrepancy between the older and more recent studies may reflect general 
improvements in diabetes care: early studies involved follow-up from the 1960s to 
1980. Epidemiological studies suggest that those who develop microalbuminuria after a 
short duration of diabetes are more likely to progress to proteinuria [138], whilst those 
with microalbuminuria and duration of diabetes > 15 years are less likely to develop 
proteinuria and have well-preserved renal function [139]. However, with general 
improvements, particularly in glycaemic and blood pressure control, it is likely that this 
pattern is altering, and the whole process of development of diabetic nephropathy is 
being slowed. Thus, microalbuminuria and proteinuria may now develop after longer 
duration of diabetes.  
Blood pressure is particularly important in the rate of progression from 
microalbuminuria to proteinuria, those with mean arterial pressure > 94 mmHg being 
more likely to progress, [137]. In those who do progress, the rate of change of AER is 
very variable from individual to individual, but is on average 20% per annum [140], so 
  
that it takes 10-15 years for proteinuria to appear. As the somewhat arbitrary cut-off 
between microalbuminuria and proteinuria is reached, patients pass through a phase of 
intermittent proteinuria, before proteinuria becomes persistent [141]. Thereafter, protein 
excretion rises continuously, perhaps into the nephrotic range. Again at this stage, the 
main determinant of proteinuria is blood pressure [142].  
In older series, the cumulative incidence of proteinuria after  
25 years' duration of type 1 diabetes was approximately 41% in those diagnosed from 
1933 to 1942, and 25% in patients diagnosed from 1953 to 1962 [143,144]. In some 
more recent series, after 15-29 years' duration of diabetes, the cumulative incidence of 
proteinuria appears to have fallen further—to 26% in 1986 data [145] and 14-17% in 
the 1990s [120,124,146]. However, in other populations, no change in the incidence of 
proteinuria by year of diagnosis has been observed [147, 148].  
The GFR remains high or normal until AER is in the high-
microalbuminuric/low-proteinuric range [125, 149], although in those with 
hyperfiltration initially, there may be a fall into the normal range. Only whenproteinuria 
is present does GFR fall below normal, the rate of fall varying from person to person 
but being relatively constant within the individual. Untreated, the average rate of fall of 
GFR is 10-12 mL/min/year, so that it takes 8-10 years from the onset of proteinuria to 
ESRD [150-152]. Again, blood pressure is the most important determinant of the rate of 
fall of GFR [142, 151]. As renal function deteriorates, fluid overload and pulmonary 
oedema may occur even in the absence of hypoalbuminaemia, probably because of poor 
left ventricular function. Hyperkalaemia results from a state of low renin and 
aldosterone production.  
  
Hypertension has long been recognized as an invariable accompaniment of 
persistent proteinuria and ESRD. The excess prevalence of hypertension in type 1 
diabetes is confined to patients with nephropathy, those individuals who have no 
evidence of nephropathy having a prevalence of hypertension similar to the non-diabetic 
population [153]. This suggests that hypertension is an integral part of diabetic 
nephropathy, perhaps arising from the same under-lying mechanisms. This view is 
supported by the recognition that blood pressure rises very early in the course of 
development of nephropathy. Indeed, some studies suggest that patients with an AER in 
the high normal range. Patients with increased risk of progression to microalbuminuria, 
also have a higher blood pressure than those with lower albumin excretion (126,154]. 
However, in other studies, blood pressure does not rise until microalbuminuria is 
already present [125, 127, 155]. Changes in blood pressure are likely to be very subtle 
at this stage and may only be documented on 24-h blood pressure monitoring, perhaps 
as reduced dipping in nocturnal diastolic blood pressure [156].  
In most cross-sectional studies, patients with micro-albuminuria have higher 
blood pressure than those with normal albumin excretion, although the levels may not 
meet a formal definition of hypertension. Blood pressure rises in parallel with albumin 
excretion. Once proteinuria is present, blood pressure untreated is > 140/90 mmHg in 
over 80% of patients, and in ESRD hypertension is almost universal.  
 In children with type 1 diabetes, the prevalence of microalbuminuria in cross-
sectional studies varies from 3% to 25%, even after a short duration of diabetes [157, 
158]. Several longitudinal studies have clarified the time course of the development of 
microalbuminuria [159-161]. In one study of children from diagnosis of diabetes, 13% 
  
developed persistent microalbuminuria after a median duration of 5 years [159]. In 
those diagnosed after puberty, there was a relatively constant rate of development of 
microalbuminuria over time, whilst in those diagnosed before puberty, there was a 
latent period followed by a more rapid onset -of microalbuminuria with time after onset 
of puberty. Thus, the cumulative probability of developing micro-albuminuria was 
similar irrespective of the age at diagnosis of diabetes. The effect of puberty on the 
prevalence of microalbuminuria was independent of glycaemic control, suggesting that 
other mechanisms, perhaps relating to sex steroids or growth factors, may be important. 
Microalbuminuria was commoner in girls, in contrast to the adult male preponderance. 
Although 19.2% were microalbuminuric on at least one occasion, in only 4.5% was 
microalbuminuria persistent for 2 years or more. In a small but detailed 3-year study of 
children before, during and after puberty, the increase in AER was significantly greater 
in pubertal and post pubertal compared to pre pubertal children [162], and the risk of 
microalbuminuria was twice as high in the pubertal compared to the pre pubertal 
children.  
Thus, transient microalbuminuria is common in adolescents around puberty and 
may relate to alterations in haemodynamic factors secondary to hormonal and growth 
factor changes. Its significance with respect to long-term glomerulosclerosis remains to 
be elucidated.  
Recent data suggest that the course of the development of nephropathy in type 2 
diabetes is in general very similar to that in type 1 diabetes, although with some 
important differences. Longitudinal studies in the Pima Indians, including data obtained 
during normal and impaired glucose tolerance, have been particularly informative.  
  
At presentation of type 2 diabetes, the AER may be normal or high [163-166]. 
As blood glucose is controlled, albumin excretion falls to within the normal range in the 
majority [166-168]. However, in 10-48%, microalbuminuria is persistent, presumably 
reflecting a long period of diabetes before diagnosis and irreversible renal structural 
damage [166, 167, 169]. Some studies suggest that the blood glucose concentration and 
glycated haemoglobin percentage at diagnosis are higher in those in whom 
microalbuminuria persists [167].  
In cross-sectional studies in established diabetes, the prevalence of 
microalbuminuria is 10-42%, depending on population selection and ethnicity [170-
175]. Higher prevalences are reported in UK Asians [171], Pima Indians [175], African-
Americans [176] and in Maori and Pacific Islanders [173] compared to Europid 
patients. The relationship of prevalence of microalbuminuria to duration of type 2 
diabetes is not as strong as in type 1 diabetes. Many longitudinal studies suggest that the 
rate of progression from normal albumin excretion to microalbuminuria is 
approximately 4% per annum—at least as high as, if not higher than, in type 1 diabetes 
[175,177-180]. Factors most consistently associated with progression include baseline 
AER, glycated haemoglobin percentage, blood pressure and serum cholesterol [177, 
179, 181].  
There is less information on progression from microalbuminuria to proteinuria in 
type 2 diabetes. In Caucasian populations, approximately one-third of microalbuminuric 
type 2 diabetic patients develop proteinuria in 5 years [182,183] and after 20 years' 
duration of type 2 diabetes, the cumulative incidence of proteinuria is 27%, similar to 
that in type 1 diabetes [184]. In the Pima Indians, more than 50% develop proteinuria 
  
within 20 years [181]. In contrast to the decline in the cumulative incidence of 
proteinuria in type 1 diabetes with onset in the 1970s and 1980s, in Pima Indians the 
incidence has doubled in the last 40 years [185], despite improvements in glucose and 
blood pressure control. This suggests a rapidly changing environmental or behavioral 
effect.  
Because of the high prevalence of hypertension in type 2 diabetes, the 
relationship of hypertension to micro-albuminuria and proteinuria is much less obvious 
than in type 1 diabetes. However, most people with micro-albuminuria or proteinuria 
have hypertension, and blood pressure rises as albuminuria increases.  
Cross-sectional studies have shown a high [186] or normal [166] GFR at 
presentation of type 2 diabetes, presumably because of variable times from onset to 
diagnosis of diabetes, or the concomitant presence of other renal diseases. However, 
careful longitudinal studies in the Pima Indians show that GFR is generally increased in 
subjects with impaired glucose tolerance who later progress to frank diabetes [181]. 
With duration of diabetes < 3 years, GFR is approximately 15% higher than in subjects 
with normal glucose tolerance. GFR remains high and stable with the onset of micro-
albuminuria, only beginning to decline when proteinuria develops [181, 187, 188]. No 
relationship of hyperfiltration at diagnosis to subsequent nephropathy has been found.  
In proteinuria, the rate of decline of GFR is similar to that in type  
1 diabetes, 10-12 mL min/ ear [184,189], although there is some suggestion that it may 
be greater in non-Caucasian subjects [190]. In England, the age-standardized acceptance 
ratios for renal replacement therapy are reported as 4.2 and 3.7 times higher in African-
  
Caribbean and lndo-Asian compared to Caucasian diabetic patients [191]. This is in 
agreement with data from several studies [192-194], including a sub analysis of the 
Modification of Diet in Renal Disease Study, which showed that despite equivalent 
achieved mean blood pressure, subjects of African descent still had a sevenfold greater 
rate of decline in renal function compared to white subjects [194]. 
Overall, the development and course of nephropathy in Europid type 2 diabetes 
is remarkably similar to that in type 1, the differences seen probably relating to delayed 
diagnosis and to the older age and consequent more marked cardiovascular disease of 
the subjects. In the ethnic minorities, the prevalence of nephropathy is higher, and 
progression to ESRD may be faster. 
Screening and diagnosis 
In all new patients with diabetes it is imperative to record the previous history of 
renal diseases or any particular history of hypertension or cardiovascular disease. Urine 
analysis and correct recording of history of supine or erect blood pressure must be done. 
Patients should be screened for microalbuminuria in the diabetic clinic. Albumin is 
measured as the earliest clinically detectable evidence of DN. Microalbuminuria is a 
misnomer for albumin in urine. A 24-urine collection is also useful for measuring total 
protein excretion and creatinine clearance. It is important to note the transient increase 
in UAE can be caused by uncontrolled hyperglycaemia; or hypertension, fever, urinary 
tract infection, congestive heart failure or physical exertion. Therefore, it is suggested 
that microalbuminuria should be confirmed by repeating the test of the urine sample 
  
over the following 3-6 months. The values have been settled to check the level of risk, 
which are listed below: 
1) Normal: 300 mg, 2) Microalbuminuria: 30-300 mg, 3) Overt proteinuria: >300 mg, 4) 
Nephrotic syndrome: >3000 mg 
The albumin/creatinine ratio (ACR) can be assessed in an early morning demonstration 
or equally well in random spot urine samples. An ACR of 2.5 is usually taken as the 
cut-off for microalbuminuria (equivalent to a UAER of >30 mg/24h). 
Cyclophilin A (CypA) 
Cyclophilin A (CypA) is an 18-kDa protein with ubiquitous characteristics. [195] 
It is mostly distributed in the cytoplasm and facilitates protein folding and protein 
trafficking. It also acts as a cellular receptor for cyclosporine A (CsA). The expression 
of CypA is relatively high in the kidney, [196] where proximal tubular epithelial cells 
(PTECs) are reported to contain considerably more CypA than other kidney 
tissues.[197] With respect to kidney diseases, the majority of research has been on the 
cellular relationship between CypA and CsA, which is used as an immunosuppressant, 
and leaves behind its secreted form. This secreted CypA (sCypA) was reported to be 
correlated with cardiovascular disease (CVD), asthma, rheumatoid arthritis (RA), and 
lung and liver injury.[198] sCypA has been suggested to be a potential biomarker and 
mediator in CVD.[199] 
In addition, sCypA is associated with inflammatory or infectious diseases such as 
RA, asthma, and periodontitis.[200] Interestingly, sCypA was also detected in diabetic 
patients’ plasma [201] and was shown to be secreted by monocytes in response to 
  
hyperglycemia, [202] indicating that sCypA could be a potential secretory marker in 
type 2 DM.[202] As a product directly produced by kidney, urine could be best measure 
for renal injury detection. In this study, the urinary level of Cyclophilin in patients with 
Diabetic Nephropathy were assayed. 
 
 
 
 
 
 
 
 
 
 
AIMS AND OBJECTIVES 
 
• To estimate the urine level of Cyclophiline-A in patients with diabetic 
nephropathy. 
• To correlate the urine level of Cyclophiline- A with Serum Creatinine, Spot urine 
Microalbumin, Albumin Creatinine Ratio, & eGFR. 
• To evaluate the correlation between urine level of cyclophiline -A and other 
several known risk factors such as Body mass Index, Blood pressure, Fasting 
plasma glucose, Postprandial plasma Glucose and blood urea. 
  
 
 
 
 
 
 
 
 
 
 
 
 
MATERIALS AND METHODS 
 
The study was conducted at Thanjavur  Medical College, Thanjavur, after getting 
the approval from the Ethical committee of Thanjavur Medical college, Thanjavur 
Hundred subjects were chosen for the study. Both males and females in the age 
group above 40 years were included and an informed consent was obtained from all of 
them. The study population included 2 groups. 
Control group consist of 50 healthy individuals (males &females) and study 
group consists of 50 patients (males &females) with Diabetic Nephropathy. 
INCLUSION CRITERIA 
  
• Patients with type-2 diabetes  
• Patients older than 18 years. 
 
EXCLUSION CRITERIA 
Patients with 
 Primary tubular diseases, 
 Recent or concurrent administration of potentially nephrotoxic drugs, 
 Acute kidney injury , 
 Terminal kidney failure requiring dialysis, 
 Known Neurological disease. 
  
 
ESTIMATION OF UREA 
PRINCIPLE  
The enzyme methodology employed in this reagent is based on the reaction first 
described by Talke and Schubert. To shorten and simplify the assay, the calculations are 
based on the discovery of Tiffany et al. that urea concentration is proportional to 
absorbance change over a fixed time interval.  
Urea + H2O UREASE  2NH3 + CO2  
NH3 + α-KG + NADH  GLDH      L-Glutamate + NAD  
1. Urea is hydrolysed in the presence of water and Urease to produce ammonia and 
carbon dioxide.  
  
2. In the presence of Glutamate Dehydrogenase (GLDH) and reduced Nicotinamide 
Adenine Dinucleotide (NADH), ammonia combines with α-ketoglutarte (α-KG) to 
produce L-Glutamate.  
3. The reaction is monitored by measuring the rate of decrease in absorbance at 340 nm 
as NADH is converted to NAD. 
REAGENT COMPOSITION  
Reagent 1 : 
Tris Buffer   100 mmol/l  
α-Ketoglutarate  5.49 mmol/l  
Urease (Jack Bean)  ≥ 10 kU/l  
GLDH (Microorganism)  ≥ 3.8 kU/l 
Reagent 2 : 
 NADH   1.66 mmol/l  
Also contains Non-reactive fillers and stabilizers. 
 R3 standard See bottle label 
REAGENT PREPARATION Reagents are liquid, ready to use.  
STABILITY AND STORAGE  
The unopened reagents are stable till the expiry date stated on the bottle and kit label 
when stored at 2–8°C. 
  
Two reagents method – substrate start  
Reagents are ready to use. After opening, reagents are stable until expiry date at 2–8°C 
if stored at appropriate conditions, closed carefully and without any contamination.  
 
 
 
 
Reagent blank Standard (Cal.) Sample 
Working reagent 1.000 ml 1.000 ml 1.000 ml 
Sample - - 0.010 ml 
Standard (Cal.) - 0.010 ml - 
Distilled water 0.010 ml - - 
 
Mixed and measured the initial absorbance after 30 sec (A1 ), start timer simultaneously 
and read again exactly after 1 min (A2 ). Measured against reagent blank. Calculated 
absorbance change ∆ Asam = (A2 –A1)/min. 
CALCULATION  
Urea (mg/dl)  = ∆ Asam – ∆A bl  x C cal             C cal = calibrator (standard) concentration 
               ∆A cal – ∆A bl 
 
 
 
  
 
 
 
 
 
 
 
ESTIMATION OF GLUCOSE 
PRINCIPLE  
Trinder’s method Glucose in the sample is oxidised to yield gluconic acid and hydrogen 
peroxide in the presence of Glucose oxidase. The enzyme peroxidase catalyses the 
oxidative coupling of 4-aminoantipyrine with phenol to yield a coloured quinonemine 
complex, with absorbance proportional to the concentration of glucose in sample. 
β-D-Glucose + H 2 O + O 2 Glucose  oxidase    Gluconic acid + H 2 O 2 
H 2 O 2 + phenol + 4AAP    Peroxidase     Red Dye + 2H 2 O 
REAGENT COMPOSITION 
Reagent 1: 
Phosphate buffer   250 mmol/l 
Glucose oxidase  >25 U/ml 
Peroxidase   >2 U/ml 
Phenol   5 mmol/l 
4-aminoantipyrine  0.5 mmol/l 
  
R2 standard   See bottle label 
REAGENT PREPARATION  
Reagents are liquid, ready to use. 
STABILITY AND STORAGE  
The unopened reagents are stable till the expiry date stated on the bottle and kit label 
when stored at 2–8 °C. 
SPECIMEN COLLECTION AND HANDLING  
Use unheamolytic serum, plasma (heparin, EDTA) or urine. It is recommended to 
follow NCCLS procedures (or similar standardized conditions). Stability after addition 
of a glycolytic inhibitor (Fluoride, monoiodoacetate, mannose): 4 
2 days  at 20–25°C 
7 days  at 4–8°C 
 
Stability in serum (separated from cellular contents, hemolysis free) without adding a 
glycolytic inhibitor: 2,5 8 
8 hours  at 25°C  
72 hours  at 4°C  
Stability of glucose in urine:  
24 hours  at 4–8°C 
  
For the determination in urine diluted the sample using redistilled water in 1 + 10 ratio. 
Discarded contaminated specimens. 
CALIBRATION  
Calibration with the standard included in the kit or the calibrator XL MULTICAL, Cat. 
No. XSYS0034 is recommended. 
QUALITY CONTROL 
 For quality control ERBA NORM, Cat. No. BLT00080 and ERBA PATH, Cat. No. 
BLT00081  were recommended. QUALITY CONTROL For quality control ERBA 
NORM, Cat. No. BLT00080 and ERBA PATH, Cat. No. BLT00081 were 
recommended. 
UNIT CONVERSION mg/dl x 0.056 = mmol/l 
 
ESTIMATION OF CREATININE ENZYMATIC 
PRINCIPLE In the first reaction, creatinase and sarcosine oxidase are used in the 
enzymatic hydrolysis of endogenous creatine to produce hydrogen peroxide, that is 
eliminated by catalase.  
Creatininase and 4-aminoantipyrine are added, and only the creatine  generated from 
creatinine by creatininase is hydrolysed sequentially by creatinase and sarcosine oxidase 
to produce hydrogen peroxide. This newly formed hydrogen peroxide is measured in a 
coupled reaction catalysed by peroxidase, with N- -ethyl-N-sulphopropyl-m-toluidine 
  
(ESPMT) as a chromogen. The absorbance of the produced complex at 546 nm is 
proportional to the creatinine concentration in the sample. 
REAGENT COMPOSITION 
 Reagent 1 : 
Good’s buffer   pH 7.5 25 mmol/l  
Creatinase    12 kU/l  
Sarcosine oxidase   8 kU/l  
Ascorbate oxidase   2 kU/l  
Catalase    200 kU/l   
ESPMT    0.47 mmol/l  
Detergent    < 1 %  
Gentamicin    < 0.1 %  
Reagent 2 : 
Good’s buffer  pH 7.5 100 mmol/l 
Creatininase    300 kU/l  
Peroxidase    20 kU/l  
4-aminoantipyrine   2.95 mmol/l  
Detergent    < 0.5 %  
  
Sodium azide   < 0.1 % 
 
REAGENT PREPARATION  
Reagents R1 and R2 are liquid, ready  for the use. 
STABILITY AND STORAGE  
The unopened reagents are stable till the expiry date stated on the bottle and kit label 
when stored at 2–8°C.  
After first opening, reagents are stable for 30 days at 2–8°C if it is stored at appropriate 
conditions, closed carefully and without any contamination. On board stability: min. 30 
days if it is refrigerated (2–10°C) and not contaminated. 
SPECIMEN COLLECTION & HANDLING  
Use serum, plasma (heparin, EDTA) ,urine. It is recommended to follow NCCLS 
procedures (or similar standardized conditions).  
Stability in serum / plasma:   
7 days   at 4–25°C  
at least 3 months  at -20°C  
in urine:  
2 days   at 20–25°C  
6 days   at 4–8°C  
  
6 months   at -20°C  
For the determination in urine use 24 hours specimen. It is important to exactly measure 
the volume of collected urine. Dilute urine samples in 1+19 ratio with distilled water 
and multiplied  the results by 20. Discarded  the contaminated specimens. 
CALIBRATION  
Calibration with calibrator XL MULTICAL, Cat. No. XSYS0034 is recommended. 
Calibration frequency: it  has been  recommended to do a calibration 
• after reagent lot change 
• as required by internal quality control procedures 
Traceability:  
This calibrator has been standardized to ID-MS. 
QUALITY CONTROL  
For quality control ERBA NORM, Cat. No. BLT00080 and ERBA PATH, Cat. No. 
BLT00081 were  recommended. 
CALCULATION  
Results were calculated automatically by the instrument. 
UNIT CONVERSION  
mg/dl x 88.4 = µmol/l 
Human CYPA (Cyclophilin A) ELISA Kit 
  
Catalogue No.: EH2918 
Size: 48T/96T 
Reactivity: Human 
Range: 1.25-80ng/ml 
Sensitivity: < 0.75ng/ml 
Application: For quantitative detection of CYPA in serum, plasma, tissue homogenates 
and other biological fluids. 
Storage: 4°C for 6 months 
NOTE: FOR RESEARCH USE ONLY. 
Kit Components 
Item Specifications(48T/96T) Storage 
Micro ELISA 
Plate(Dismountable) 
8 ×6 or 8×12 4°C/-20°C 
Lyophilized Standard 1 vial or 2 vial 4°C/-20°C 
Sample / Standard dilution 
buffer 
10ml/20ml 4°C 
Biotin- detection antibody 
(Concentrated) 
60ul/120ul 4°C 
Antibody dilution buffer 5ml/10ml 4°C 
HRP-Streptavidin 60ul/120ul 4°C(shading light) 
  
Conjugate(SABC) 
SABC dilution buffer 5ml/10ml 4°C 
TMB substrate 5ml/10ml 4°C(shading light) 
Stop solution 5ml/10ml 4°C 
Wash buffer (25X) 15ml/30ml 4°C 
Plate Sealer 3/5pieces  
Product Description 1 copy  
 
Principle of the Assay 
This kit is based on sandwich enzyme-linked immune-sorbent assay technology. Anti- 
CYPA antibody is pre-coated onto 96-well plates. And the biotin conjugated anti- 
CYPA antibody  has been used  to detect  antibodies. The standards, test samples and 
biotin conjugated detection antibody are added to the wells subsequently, and washed 
with wash buffer. HRP-Streptavidin  is added and unbound conjugates are washed away 
with wash buffer. TMB substrates  has been used to visualize HRP enzymatic reaction. 
TMB is    catalyzed by HRP to produce a blue color product that changed into yellow 
after adding acidic stop solution. The density of yellow is proportional to the CYPA 
amount of sample captured in plate. Read the O.D. absorbance at 450nm in a microplate 
reader, and then the concentration of CYPA  will be calculated. 
Precautions for Use 
  
1. For the inspection and the validity of experiment operation , the appropriateness 
of sample dilution proportion, pilot experiment using standards and a small 
number of samples  are  recommended. 
2. The plate should be kept dry, after opening and before using the same. 
3. Before using the Kit, the tubes were spun. 
4. All the components were brought to the bottom of tubes. 
5. TMB reagents were stored in a dark avoiding light. 
6. Washing process is very important; if it is fully washed it will easily cause a false 
positive. 
7. Duplication of well assay was recommended for both standard and sample 
testing. 
8. Micro plate were never allowed to fully  dry at the assay, as it will inactivate 
active components on plate. 
9. Used tips and tubes were discarded to avoid cross contamination. 
10. Reagents from single batch were used at a time 
 
Manual Washing 
Discarded the solution in the plate without touching the side walls. Clapped the plate on 
absorbent filter papers or other absorbent material. Filled each well completely with 
350ul wash buffer and soaked for 1 to 2 minutes, then aspirated contents from the plate, 
and clapped the plate on absorbent filter papers or other absorbent material. Repeated 
this procedure two more times for a total of THREE washes. 
  
Automated Washing 
Aspirated all wells, then washed plate THREE times with 350ul wash buffer. After the 
final washing, inverted the plate, and clapped the plate on absorbent filter papers or 
other absorbent material. It was recommended that the washer be set for a soaking time 
of 1 minute. 
Sample Collection and Storage 
Isolated the test samples soon after the collection, then, analyzed immediately (within 2 
hours).  
Serum: Allowed samples to clot for 2 hours at room temperature or overnight at 4°C 
before centrifugation for 20 minutes at approximately 1000×g. Collected the 
supernatant and carried out the assay immediately. Blood collection tubes should be 
disposable, non-pyrogenic, and non-endotoxin. 
• Plasma: Collected plasma using EDTA-Na2 as an anticoagulant. Centrifuged 
samples for 15 minutes at 1000×g at 2 - 8°C within 30 minutes of collection. 
Collected the supernatant and carried out the assay immediately. 
Note:  
Samples to be used within 5 days may be stored at 4°C, otherwise the samples must be 
stored at -20°C (≤1 month) or -80°C (≤2 months) to avoid the loss of bioactivity and 
contamination. Hemolyzed samples are not suitable for use in this assay. 
Sample Dilution Guideline 
  
End user should estimate the concentration of the targeted   protein in the test sample 
first, and then select a proper dilution factor to make the diluted target protein 
concentration that falls the optimal detection range of the kit. Diluted the sample with 
the provided dilution buffer, and several trials may be  practiced when it is necessary. 
The test sample must be well mixed with the dilution buffer. And also standard curves 
and sample should be made in pre-experiment. 
 High target protein concentration (800-8000ng/ml): Dilution: 1:100. (i.e. Add 1µl 
of sample into 99 µl of Sample / Standard dilution buffer.) 
 Medium target protein concentration (80-800ng/ml): Dilution: 1:10.( i.e. Add 10 
µl of sample into 90 µl of Sample / Standard dilution buffer.) 
 Low target protein concentration (1.25-80ng/ml): Dilution: 1:2.( i.e. Add 50 µl of 
sample into 50 µl of Sample / Standard dilution buffer.) 
 Very low target protein concentration (≤1.25ng/ml): Unnecessary to dilute, or 
dilute at 1:2. 
Reagent Preparation and Storage 
All the reagents should be brought to the room temperature before use. 
1, Wash Buffer: 
Diluted the 30mL of Concentrated Wash Buffer into 750 mL of Wash Buffer with 
deionized or distilled water. Put unused solution back at 4°C.  
2, Standard: 
  
1) 80ng/ml of standard solution was prepared  by adding 1 ml of Sample / Standard 
dilution buffer into one Standard tube, and keeping the tube at the room 
temperature for 10 min and allowing it to mix thoroughly. 
2)  6 Eppendorf  tubes were labeled with 40ng/ml, 20ng/ml,10ng/ml, 5ng/ml, 
2.5ng/ml, 1.25ng/ml, respectively.  
3) Aliquot 0.3 ml of the Sample / Standard dilution buffer into each tube. 
4)  0.3 ml of the above 80ng/ml standard solution was transferred into 1st tube and 
mixed thoroughly. 
5)  Then 0.3 ml from 1st tube was transferred to 2nd tube and mixed thoroughly.  
6) Later 0.3ml from 2nd tube was transferred to 3rd tube and mixed thoroughly, and 
so on. 
Note: 
The standard solutions are best used within 2 hours. The standard solution should be at 
4°C for up to12 hours. Or store at -20 °C for up to 48 hours. Avoid the repetition of 
freeze-thaw cycles. 
3, Preparation of Biotin- detection Antibody working solution 
Prepared within 1 hour before the experiment. 
1) Calculated the total volume of the working solution: 0.1 ml / well × quantity of 
wells. (Allow 0.1-0.2 ml more than the total volume) 
  
2) Diluted the Biotin- detection antibody with Antibody dilution buffer at 1:100 and 
mixed thoroughly. (i.e. Add 1 µl of Biotin- detection antibody into 99 µl of 
Antibody dilution buffer.) 
4, Preparation of HRP-Streptavidin Conjugate (SABC) working solution: 
Prepared within 30min before the experiment. 
1) Calculated the total volume of the working solution: 0.1 ml / well × quantity of 
wells. (Allow 0.1-0.2 ml more than the total volume) 
2) Diluted the SABC with SABC dilution buffer at 1:100 and mix thoroughly. (i.e. 
Add 1 µl of SABC into 99 µl of SABC dilution buffer.) 
Assay Procedure 
Before adding to wells, equilibrated the SABC working solution and TMB substrate 
for at least 30 min at the room temperature (37 °C). When diluting samples and 
reagents, they must be mixed completely and evenly. It is recommend to plot a 
standard curve for each test. 
1. Set standard, test sample and controlled the (zero) wells on the pre-coated 
plate respectively, and then, recorded their positions. It is recommend to 
measure  the each standard and sample in duplicate. Washed plate 2 times 
before adding standard, sample and controlled the (zero) wells 
2. Aliquot 0.1ml of 80ng/ml, 40ng/ml, 20ng/ml, 10ng/ml, 5ng/ml, 2.5ng/ml, 
1.25ng/ml, standard solutions into the standard wells. 
3. 0.1 ml of Sample / Standard dilution buffer added into the control (zero) well. 
  
4. 0.1 ml of properly diluted sample (Human serum, plasma, tissue homogenates 
and other biological fluids.) added into test sample wells. 
5. Sealed the plate with a cover and incubated at 37 °C for 90 min. 
6. Removed the cover and discarded the plate content, clapped the plate on the 
absorbent filter Papers or other absorbent material.  
7. 0.1 ml of Biotin- detection antibody working solution is added into the above 
wells (standard, test sample & zero wells). 
8. Sealed the plate with a cover and incubated at 37°C for 60 min. 
9. Removed the cover, and plate was washed 3 times with Wash buffer. 
10. 0.1 ml of SABC working solution was added into each well covered the plate 
and incubated at 37°C for 30 min. 
11. Removed the cover and plate was washed 5 times with the Wash buffer, and 
each time let the wash buffer stay in the wells for 1-2 min. 
12. 90 µl of TMB substrate into each well, covered the plate and incubate at 37°C 
in dark within 15-30 min. (Note: This incubation time is for reference use 
only, the optimal time should be determined by end user.) And the shades of 
blue can be seen in the first 3-4 wells (with most concentrated CYPA 
standard solutions), the other wells showed no obvious colour. 
13. Added 50 µl of Stop solution into each well and mixed thoroughly. The 
colour changed into yellow immediately. 
14. Read the O.D. absorbance at 450 nm in a micro plate reader immediately 
after adding the stop solution. 
  
For the calculation, (the relative O.D.450) = (the O.D.450 of each well) – (the O.D.450 
of Zero well).The standard curve was plotted as the relative O.D.450 of each standard 
solution (Y) vs. the respective concentration of the standard solution (X). The CYPA 
concentration of the samples can be interpolated from the standard curve. 
Note: If the samples measured were diluted, multiplied the dilution factor to the 
concentrations from interpolation to obtain the concentration before dilution. 
 
 
 
Summary: 
1. Washed plate 2 times before adding standard, sample and controlled the (zero) 
wells 
2. Added 100µL standard or sample to each well for 90 minutes at 37°C 
3. added 100µL Biotin- detection antibody working solution to each well for 60 
minutes at 37°C 
4. Aspirated and washed 3 times 
5. Added 100µL SABC working solution to each well. Incubated for 30 minutes at 
37°C 
6. Aspirated and washed 5 times 
7. Added 90µL TMB substrate. Incubated 15 -30 minutes at 37°C 
8. Added 50µL Stop Solution. Read at 450nm immediately 
  
9. Calculation of results 
Typical Data & Standard Curve 
Results of a typical standard run of a CYPA ELISA Kit are shown below. This standard 
curve was generated at our lab for demonstration purpose only. Each user should obtain 
their own standard curve as per experiment. (N/A=not applicable) 
X  ng/ml 0 1.25 2.5 5 10 20 40 80 
Y OD450 0.035 0.097 0.158 0.352 0.611 1.112 1.729 2.298 
 
Specificity 
This assay has high sensitivity and excellent specificity for detection of CYPA. No 
significant cross-reactivity or interference between CYPA and analogues were 
observed. 
Note: 
Limited by current skills and knowledge, it is impossible for us to complete the cross-
reactivity detection between the CYPA and all the analogues, therefore, cross reaction 
may still exist. 
Recovery 
Matrices listed below were spiked with certain level of CYPA and the recovery rates 
were calculated by comparing the measured value to the expected amount of CYPA in 
samples. 
  
Matrix Recovery range (%) Average(%) 
serum(n=5)  85-99 91 
EDTA plasma(n=5) 88-101 94 
heparin plasma(n=5) 85-104 92 
 
 
 
Linearity 
The linearity of the kit was assayed by testing samples spiked with appropriate 
concentration of CYPA and their serial dilutions. The results were demonstrated by the 
percentage of calculated concentration to the expected. 
Sample 1:2 1:4 1:8 1:16 
serum(n=5) 87-102% 85-105% 87-98% 88-104% 
EDTA 
plasma(n=5) 
82-95% 84-100% 83-101% 86-94% 
heparin 
plasma(n=5) 
82-93% 81-97% 80-98% 82-100% 
 
Precision 
Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high 
level CYPA were tested 20 times on one plate, respectively. 
  
Inter-assay Precision (Precision between assays): 3 samples with low, middle and high 
level CYPA were tested on 3 different plates, 8 replicates in each plate. 
CV (%) = SD/mean X 100 
Intra-Assay:  CV<8% 
Inter-Assay:  CV<10% 
Stability 
The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this 
kit is less than 10% within the expiration date under appropriate storage condition. 
Standard(n=5) 37°C for 1 months 4°C for 6 months 
Average (%) 80 95-100 
 
To minimize extra influence on the performance, operation procedures and lab 
conditions, especially room temperature, air humidity, incubator temperature should be 
strictly controlled. It is also strongly suggested that the whole assay is performed by the 
same operator from the beginning to the end. 
 
 
 
 
 
  
 
 
 
 
 
 
RESULTS AND 
STATISTICS 
 
 
 
 
 
 
  
GENDER MATCHED ANALYSIS 
BETWEEN CONTROL AND STUDY GROUP 
Chi-square test  
Sex 
Control Group Study Group Total 
Statistical inference 
n % n % n % 
Male 24 48.0% 28 56.0% 52 52.0% X2=0.641 
Df=1  
.423>0.05  
Not Significant 
Female 26 52.0% 22 44.0% 48 48.0% 
Total 50 100.0% 50 100.0% 100 100.0%  
 
 
 
 
 
 
 
 
 
 
  
 
AGE MATCHED ANALYSIS 
BETWEEN CONTROL AND STUDY GROUP 
 
Chi-square test  
Age (years) 
Control Group Study Group Total 
Statistical inference 
n % n % n % 
Below 40yrs 3 6.0% 0 .0% 3 3.0% X2=59.267 
Df=3  
.000<0.05  
Significant 
41 to 50yrs 47 94.0% 13 26.0% 60 60.0% 
51 to 60yrs 0 .0% 22 44.0% 22 22.0% 
Above 61yrs 0 .0% 15 30.0% 15 15.0% 
Total 50 100.0% 50 100.0% 100 100.0%  
 
 
 
 
 
 
 
  
COMPARISON OF PARAMETERS 
BETWEEN CONTROL AND STUDY GROUP 
T-Test 
 n Mean S.D t Df Statistical inference 
Age (years)       
Control 50 45.16 3.165 
11.688 98 
.000<0.05  
Significant Study 50 56.18 5.868 
Duration (years)       
Control 50 .00 .000 
18.360 98 
.000<0.05  
Significant Study 50 12.58 4.845 
Fasting (mg/dl)       
Control 50 90.56 8.894 
8.526 98 
.000<0.05  
Significant Study 50 127.38 29.212 
Creatinine (mg)       
Control 50 .7570 .13256 10.196 98 
.000<0.05  
Significant 
Study 50 1.3240 .37019    
eGFR (ml/min)       
Control 50 111.64 6.586 
4.275 98 
.000<0.05  
Significant Study 50 98.68 20.400 
ACR (mg/g)       
Control 50 11.92 2.039 5.317 98 .000<0.05  
  
Study 50 248.62 314.790 Significant 
CYP A (ng/ml)       
Control 50 .7896 .12144 
6.930 98 
.000<0.05  
Significant Study 50 1.8800 1.10589 
BP (mmHg) -1       
Control 50 114.40 5.014 
9.130 98 
.000<0.05  
Significant Study 50 141.60 20.460 
BP (mmHg) - 2       
Control 50 74.40 5.014 
9.319 98 
.000<0.05  
Significant Study 50 90.68 11.289 
Urea (mg/dl)       
Control 50 24.92 3.510 
5.940 98 
.000<0.05  
Significant Study 50 43.98 22.416 
 
 
 
 
 
 
 
 
 
 
  
 
DESCRIPTIVE STATISTICS 
 
Variables 
Control Group 
(n=50) 
Study Group 
(n=50) 
Min. Max. Mean S.D Min. Max. Mean S.D 
Age (years) 40 50 45.16 3.165 45 65 56.18 5.868 
Duration (years) 0 0 .00 .000 5 20 12.58 4.845 
Fasting (mg/dl) 78 110 90.56 8.894 91 190 127.38 29.212 
Creatinine (mg) .50 .90 .7570 .13256 .90 2.40 1.3240 .37019 
eGFR (ml/min) 98 126 111.64 6.586 70 130 98.68 20.400 
ACR (mg/g) 8 16 11.92 2.039 15 945 248.62 314.790 
CYP A (ng/ml) .50 .90 .7896 .12144 .90 5.00 1.8800 1.10589 
BP (mmHg) -1 110 120 114.40 5.014 110 170 141.60 20.460 
BP (mmHg) - 2 70 80 74.40 5.014 70 104 90.68 11.289 
Urea (mg/dl) 20 30 24.92 3.510 20 90 43.98 22.416 
 
 
 
 
 
 
 
  
PEARSONS CORRELATION 
Control Group (n=50) 
 
cyp A (ng/ml) Correlation value Statistical inference 
AGE (YEARS) .119 .412>0.05 NS 
DURATION (YEARS) - - 
FASTING (mg/dl) .101 .483>0.05 NS 
CREATININE (mg) .640(**) .000<0.01 S 
eGFR (ml/min) .395(**) .004<0.01 S 
ACR (mg/g) .235 .101>0.05 NS 
BP (mmHg) -1 -.004 .979>0.05 NS 
BP (mmHg) - 2 -.004 .979>0.05 NS 
UREA (mg/dl) -.026 .856>0.05 NS 
N 50  
 
** Correlation is significant at the 0.01 level 
Study Group (n=50) 
cyp A (ng/ml) Correlation value Statistical inference 
AGE (YEARS) .780(**) .000<0.01 S 
DURATION (YEARS) .808(**) .000<0.01 S 
FASTING (mg/dl) -.187 .194>0.05 NS 
CREATININE (mg) .844(**) .000<0.01 S 
eGFR (ml/min) -.826(**) .000<0.01 S 
  
ACR (mg/g) .902(**) .000<0.01 S 
BP (mmHg) -1 .842(**) .000<0.01 S 
BP (mmHg) - 2 .768(**) .000<0.01 S 
UREA (mg/dl) .883(**) .000<0.01 S 
N 50  
 
** Correlation is significant at the 0.01 level 
 
 
 
 
 
 
 
 
 
COMPARISON OF GENDER 
BETWEEN CONTROL AND STUDY GROUP 
 
sex Control Group Study Group 
  
 
 
 
 
 
 
 
 
 
 
 
 
COMPARISON OF AGE DISTRIBUTION  
BETWEEN CONTROL AND STUDY GROUP 
 
Age wise distribution Study group Control Group 
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Male Female
Comparison of Gender
Control Group
Study Group
Male 24 28 
Female 26 22 
  
Below 40yrs 0 3 
41 to 50yrs 13 47 
51 to 60yrs 22 0 
Above 61yrs 15 0 
 
 
 
 
 
 
DURATION OF DIABETES IN STUDY GROUP 
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Below 40yrs 41 to 50yrs 51 to 60yrs Above 61yrs
Age Distribution 
Study group Control Group
Duration of disease study group Control Group 
< 10 years 17 0 
10-15 years 17 0 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
COMPARISON OF FASTING BLOOD SUGAR  
BETWEEN CONTROL AND STUDY GROUP 
 
34%
34%
32%
Duration Of Diabetes In Study Group
< 10 years 10-15 years >15 years
>15 years 16 0 
  
Fasting Sugar Control Group Study Group 
< 100 mgs/dL 39 8 
100-150 mgs/dL 11 13 
>150 mgs/dL 0 29 
 
 
 
 
 
 
 
 
 
COMPARISON OF CREATININE LEVEL  
BETWEEN CONTROL AND STUDY GROUP 
Creatinine  
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Creatinine level Study Group Control Group 
< 1 mgs/dL 10 50 
1-1.49 mgs/dL 30 0 
1.5-2 mgs/dL 6 0 
>2 mgs/dL 4 0 
 
 
 
 
 
 
COMPARISON OF eGFR  
BETWEEN CONTROL AND STUDY GROUP 
 
eGFR Study Group Control Group 
< 90 ML/ MIN 18 0 
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Creatinine Comparison
Study Group
Control Group
  
90-120 ML/MIN 26 47 
120-150 ML/MIN 6 3 
 
 
 
 
 
 
 
 
 
COMPARISON OF ALBUMIN CREATININE RATIO  
BETWEEN CONTROL AND STUDY GROUP 
 
 
ACR Study Group Control Group 
< 30 mG/L 6 50 
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e GFR COMPARISON
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Control Group
  
30-300 mG/L 20 0 
> 300 mG/L 24 0 
 
 
 
 
 
 
COMPARISON OF URINARY CYCLOPHILIN A LEVEL 
BETWEEN CONTROL AND STUDY GROUP  
 
cyp A LEVELS Study Group Control Group 
<0.89 0 42 
0.9 - 2 33 8 
> 2 17 0 
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COMPARISON OF SYSTOLIC BLOOD PRESSURE BETWEEN 
CONTROL AND STUDY GROUP  
 
Systolic Blood 
Pressure Study Group Control Group 
< 120 6 28 
120-139 18 22 
140-159 10 0 
> 160 16 0 
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COMPARISON OF UREA BETWEEN  
CONTROL AND STUDY GROUP 
 
Urea Study Group Control Group 
< 40 mgs/dL 29 50 
40 - 59 mgs/dL 7 0 
60-79 mgs/dL 9 0 
> 80 mgs/dL 5 0 
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DISCUSSION 
Type 2 diabetes mellitus (DM) is the most common single cause of end-stage 
renal disease. Albuminuria is the most commonly used marker to predict onset of 
diabetic nephropathy (DN) without enough sensitivity and specificity to detect early 
DN. This is the first study to identify urinary cyclophilin A (CypA) as a new biomarker 
for early DN. 
Type 2 diabetes mellitus (DM) is the most common single cause of end-stage 
renal disease (ESRD). ESRD in almost half of patients is due to diabetic nephropathy 
(DN), and these cases have the worst outcome compared to patients with other causes of 
ESRD. Although there are many novel drugs for DM, there are no specific curative 
treatments yet for DN. Reasons for poor outcome include inadequate markers and the 
complicated mechanisms of DN. Currently, the stage of severity is determined 
0
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Urea comparison
Study Group
Control Group
  
according to the levels of albuminuria. Albuminuria is the most commonly used marker 
to predict onset and progression of DN clinically. However, this traditional marker for 
DN lacks both sensitivity and specificity to detect early stage of DN. Furthermore, some 
DN patients with ESRD do not present with significant albuminuria. The lack of a 
strong association between glomerular filtration rate (GFR) and albuminuria suggests 
that an alternative to this albuminuria-based staging system is needed. Some studies 
have noted the existence of pathological change before microalbuminuria. Therefore, 
even if microalbuminuria can be regarded as the earliest manifestation of DN, it is 
possible that a new biomarker for DN exists. Recently, different markers of DN were 
reviewed including fibroblast growth factor 23, tubular markers (kidney injury molecule 
1, neutrophil gelatinase-associated lipocalin, and liver-type fatty acid-binding protein 
[L-FABP]), inflammatory markers (interleukin 6 [IL-6], IL-8, monocyte 
chemoattractant protein 1, and interferonγ–inducible protein), urinary 8-hydroxy-20-
deoxyguanosine, serum cystatin C, and so on. Among these, genetic susceptibility 
almost always leads to irreversible DN, and detection of the clinical markers mostly 
occurs too late to diagnose and monitor the progression of DN. As such, it is crucial to 
find an earlier and reliable marker for DN. Earlier diagnosis and intervention may 
provide an opportunity to stop the permanent damage caused by DN. 
The concentration of urinary CypA correlated well with the progression of renal 
function. Urinary CypA is a good biomarker for early DN detection in humans and it 
can be released from either mesangial or tubular cells. 
  
In the study of Urinary Cyclophiline A were found to be significantly increased 
in patients with Diabetic nephropathy mean (0 .7896 ± 0.12144) when compared with 
control group mean (1.8800 ± 1.10589). 
ACR level were progressively increased in cases than control and shows positive 
correlation with Urinary Cyclophilin A (0.235). 20% of the patients of the study group 
having normal ACR value with increased urinay Cyclophiline level. So we can diagnose 
Diabetic Nephropathy prior to appearance of albuminuria. The concentration of urinary 
CypA was more than 0.7250 ng/mL, we could diagnose the silent stage of DN.  
The concentration of urinary CypA correlated well with duration of Diabetes 
mellitus (0.808). 
The concentration of urinary CypA correlated well with Serum creatinine 
(0.844). 
The concentration of urinary CypA correlated well with Blood Urea (0.833). 
The concentration of urinary CypA negatively correlated with e GFR.  
When patients in different stages of Diabetic nephropathy were compared 
Urinary Cyclophiline A level were found to be progressively increased from stage 2 to 
5. This observation shows that Urinary Cyclophiline increases as renal function declines 
and inversely correlates with e GFR (0.395). 
Serum creatinine and blood urea were progressively increased in cases then 
control and shows positive correlation with urinary Cyclophilin A. 
  
Fasting blood sugar were significantly higher in cases (127.38±29.212) than in 
controls (90.56±8.894). 
Blood pressure were significantly higher in cases (141.60±20.460) than in 
controls (114.40±5.014). 
 
 
 
 
CONCLUSION 
 The present study demonstrated Urinary Cyclophiline A concentrations 
are significantly increased in patients with Diabetic Nephropathy. Urinary 
Cyclophiline A correlated well with other markers of Nephropathy. Urinary 
Cyclophiline A significantly increased even in early stages of Diabetic 
Nephropathy. 
 Urinary Cyclophiline A estimation can be used for the early diagnosis 
of renal damage due to long standing diabetes mellitus. 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
LIMITATIONS OF THE STUDY 
 
 
• The sample size was small. 
• Calculation of e GFR is based on serum creatinine which is a crude marker for  
e GFR estimation. 
FUTURE SCOPE OF THE STUDY 
 
 Urinary Cyclophilin A level may be used as alternative biomarker for 
microalbumin. 
 Urinary Cyclophilin A level may be used as alternative biomarker for 
vascular diseases and coronary artery diseases. 
 Urinary Cyclophilin A monoclonal antibodies may be developed and 
used for treatment of diabetic nephropathy. 
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STUDY OF URINARY CYCLOPHILIN A LEVEL IN DIABETIC 
NEPHROPATHY 
 
PROFORMA 
NAME OF THE PATIENT:      O.P NO/I.P NO: 
AGE    : 
OCCUPATION  : 
ADDRESS   : 
COMPLAINTS  : 
PAST HISTORY: 
PERSONAL HISTORY: 
FAMILY HISTORY: 
DRUG HISTORY: 
GENERAL EXAMINATION: 
HT:                    WT:                BMI:                     PR:                     BP: 
SYSTEMIC EXAMINATION: 
CVS:                         RS:            
ABD:                        CNS: 
INVESTIGATIONS  :  
BLOOD 
1. BLOOD SUGAR:  FBS: PPBS:  
2. SERUM CREATININE 
URINE 
1. URINE LEVEL OF CYCLOPHILINE- A 
2. URINE ALBUMIN 
3. ALBUMIN CREATININE RATIO 
4. eGFR 
  
 
 
 
 
  
 
ABBREVIATIONS 
 
CKD     Chronic Kidney Disease 
ESRD     End Stage Renal Disease 
GFR     Glomerular Filteration Rate 
Cyp A     Cyclophilin A 
DN     Diabetic Nephropathy 
ACR     AlbuminCreatinineRatio 
CVD     Cardio VascularDisease 
DKD     Diabetic Kidney Disease 
AER     Albumin ExcretionRate 
 
  
MASTER CHART I - CONTROL GROUP 
SL.NO SEX 
AGE 
(YEARS) 
DURATION 
(YEARS) 
FASTING 
(mg/dl) 
CREATININE 
(mg) 
eGFR 
(ml/min) 
ACR 
(mg/g) 
CYP A 
(ng/ml) 
BP 
(mmHg) 
UREA 
(mg/dl) 
1 M 47 0 85 0.73 117 12 0.74 110/70 22 
2 F 43 0 79 0.69 103 10 0.69 120/80 25 
3 M 40 0 88 0.81 111 13 0.58 120/80 30 
4 F 42 0 80 0.52 113 12 0.55 110/70 21 
5 M 45 0 92 0.54 109 11 0.66 120/80 26 
6 M 43 0 100 0.61 106 10 0.71 110/70 20 
7 F 41 0 90 0.50 102 9 0.90 110/70 27 
8 F 46 0 97 0.59 104 11 0.64 120/80 23 
9 M 49 0 82 0.64 107 10 0.50 110/70 30 
10 M 44 0 78 0.57 105 15 0.90 120/80 24 
11 F 48 0 93 0.70 110 12 0.60 110/70 20 
12 F 40 0 110 0.53 108 11 0.50 110/70 25 
13 M 47 0 102 0.60 111 8 0.54 120/80 23 
14 F 49 0 79 0.57 98 14 0.57 110/70 27 
15 M 41 0 81 0.59 101 9 0.79 120/80 29 
  
16 F 44 0 78 0.64 103 16 0.82 120/80 20 
17 M 48 0 92 0.56 114 10 0.85 110/70 30 
18 M 50 0 105 0.79 117 14 0.77 110/70 21 
19 F 43 0 99 0.80 120 12 0.81 120/80 29 
20 F 41 0 80 0.65 113 15 0.75 120/80 22 
21 M 44 0 91 0.77 108 11 0.78 110/70 25 
22 M 45 0 86 0.69 105 8 0.69 120/80 30 
23 F 43 0 84 0.57 101 9 0.71 110/70 24 
24 M 49 0 108 0.90 120 16 0.90 120/80 20 
25 F 50 0 80 0.89 118 14 0.87 110/70 23 
26 F 45 0 89 0.74 111 10 0.81 110/70 28 
27 M 47 0 78 0.80 119 15 0.76 120/80 21 
28 F 46 0 90 0.84 108 12 0.85 110/70 29 
29 M 41 0 102 0.79 126 11 0.90 110/70 25 
30 M 43 0 79 0.90 112 14 0.79 110/70 30 
31 F 40 0 88 0.84 119 13 0.82 120/80 26 
32 M 43 0 85 0.87 110 11 0.86 110/70 22 
33 F 48 0 94 0.89 107 10 0.89 110/70 20 
  
34 F 50 0 92 0.90 109 12 0.9 120/80 24 
35 M 49 0 88 0.86 107 10 0.87 110/70 27 
36 F 47 0 90 0.78 105 13 0.83 120/80 30 
37 M 41 0 85 0.87 109 12 0.85 120/80 21 
38 M 45 0 88 0.84 112 14 0.89 110/70 28 
39 F 43 0 100 0.90 120 13 0.90 120/80 24 
40 F 47 0 102 0.88 124 10 0.86 110/70 20 
41 M 50 0 105 0.90 119 12 0.90 110/70 23 
42 F 49 0 99 0.89 110 11 0.88 120/80 30 
43 F 45 0 79 0.79 113 14 0.87 110/70 25 
44 F 42 0 84 0.80 115 12 0.89 110/70 21 
45 M 47 0 89 0.85 117 10 0.90 120/80 29 
46 M 50 0 101 0.90 120 15 0.89 110/70 27 
47 F 43 0 97 0.90 110 13 0.86 120/80 30 
48 F 48 0 90 0.88 119 11 0.90 110/70 24 
49 M 41 0 95 0.90 121 14 0.90 110/70 20 
50 F 46 0 100 0.89 116 12 0.89 120/80 26 
 
  
MASTER CHART II - STUDY GROUP 
SL.NO SEX 
AGE 
(YEARS) 
DURATION 
(YEARS) 
FASTING 
(mg/dl) 
CREATININE 
(mg) 
eGFR 
(ml/min) 
ACR 
(mg/g) 
CYP A 
(ng/ml) 
BP 
(mmHg) 
UREA 
(mg/dl) 
1 M 49 6 92 0.93 128 15 0.91 120/80 20 
2 M 49 6 92 0.93 128 15 0.91 120/80 20 
3 F 47 5 99 0.95 127 17 1.00 110/70 27 
4 F 50 6 107 0.97 129 20 0.97 110/70 21 
5 M 52 9 123 1.11 115 45 1.10 130/86 24 
6 M 54 10 135 1.19 117 52 1.00 120/80 22 
7 M 53 8 127 1.17 111 48 1.10 130/86 28 
8 F 50 9 138 1.1 118 37 1.00 120/80 25 
9 M 58 15 170 1.2 90 70 1.30 146/96 30 
10 F 56 14 177 1.27 94 75 1.25 140/90 35 
11 M 57 13 184 1.22 96 82 1.50 146/96 40 
12 M 55 14 171 1.23 92 84 1.60 140/90 31 
13 M 60 15 112 1.29 98 175 2.00 160/100 66 
14 F 63 16 125 1.35 84 212 2.10 156/100 53 
15 M 62 15 110 1.38 86 317 2.30 160/100 64 
  
16 M 61 17 117 1.32 81 188 2.22 160/100 49 
17 F 65 20 115 1.5 70 780 4.00 170/104 85 
18 F 63 18 120 1.6 73 890 2.50 160/100 77 
19 M 62 17 105 2.28 71 756 3.30 170/104 81 
20 F 60 19 114 2.3 74 945 4.50 170/104 73 
21 M 45 6 95 0.91 128 18 0.92 110/70 22 
22 M 48 5 92 0.94 127 19 0.98 120/80 27 
23 F 46 6 97 0.99 130 22 0.90 110/70 20 
24 F 49 5 91 0.96 121 25 0.97 110/70 25 
25 F 50 8 125 1.13 112 55 1.00 130/86 30 
26 M 52 9 139 1.2 110 43 1.10 130/86 21 
27 M 54 8 128 1.19 115 62 1.00 120/80 29 
28 F 53 10 136 1.1 119 59 1.10 120/80 26 
29 M 56 13 176 1.3 91 73 1.20 146/96 39 
30 F 58 15 188 1.22 98 79 1.40 140/90 32 
31 M 57 13 172 1.29 99 81 1.60 146/96 34 
32 F 55 14 190 1.3 90 87 1.80 140/90 38 
33 M 60 16 113 1.3 80 104 2.00 160/100 69 
  
34 F 62 15 129 1.4 90 277 2.40 156/100 55 
35 M 61 17 120 1.36 85 314 2.30 160/100 43 
36 F 63 16 126 1.33 84 294 2.20 156/100 48 
37 M 65 19 102 1.8 72 826 4.00 170/104 74 
38 F 63 17 108 1.6 73 890 2.50 160/100 85 
39 F 60 20 115 2 71 756 3.30 170/104 88 
40 M 62 18 100 2.4 70 932 5.00 170/104 90 
41 F 49 6 94 0.99 126 20 0.97 120/80 23 
42 M 47 5 109 0.9 129 24 1.00 110/70 20 
43 M 54 8 140 1.2 117 64 1.10 120/80 28 
44 F 50 10 138 1.1 112 38 1.00 130/86 30 
45 M 57 14 181 1.3 99 76 1.80 146/96 33 
46 M 55 13 176 1.2 92 88 1.50 146/96 39 
47 F 60 17 110 1.4 80 340 2.10 160/100 61 
48 M 63 16 126 1.3 87 275 2.30 156/100 46 
49 M 65 20 100 2.3 73 898 3.00 160/100 79 
50 F 64 18 120 1.5 72 769 5.00 170/104 74 
 
